Fig. 5: Mean difference in FVC.
From: Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
ALAACRC American Lung Association Asthma Clinical Research Centers, AUC area under curve, BID twice daily, CI confidence interval, FVC forced vital capacity, LABA long-acting β2-agonist, LAMA long-acting muscarinic agonist, LTRA leukotriene receptor antagonist, NR not reported, NS non-significant, QD once daily.
